Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …

Background Long-acting cabotegravir and rilpivirine administered monthly or every 2 months
might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-…

Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …

Background Peripartum administration of single-dose nevirapine reduces mother-to-child
transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-…

Background Optimal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent
contributor to morbidity and mortality among people with HIV, have not been systematically …

Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate
pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in human …

Background: Many HIV-infected individuals present with advanced HIV disease. These
patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for …

Background Young children living with HIV have few treatment options. We aimed to assess
the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children …

Background Antiretroviral therapy (ART) management is challenging for individuals in
resource-limited settings presenting for third-line treatment because of complex resistance patterns…

Chronic obstructive pulmonary disease (COPD) is an under recognized complication of HIV
infection. It is estimated that up to 25% of HIV infected people may have COPD. HIV is …